Relatively poor regulation of blood pressure in patients with type-2 diabetes mellitus in the primary-care setting and specialists' practice in the Netherlands;Matige bloeddrukregulatie bij patiënten met diabetes mellitus type 2 in de eerste en tweede lijn

Nederlands Tijdschrift voor Geneeskunde

Volumn 148, Issue 12, 2004, Pages 570-574

  Van Der Horst Schrivers, A N A ^a,b   Ubink Veltmaat, L J ^a,c   Van Der Horst, I C C ^b   Bilo, H J G ^a   Lambert, J ^a  

^a ISALA HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; DIABETES MELLITUS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY MEDICAL CARE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; ENDOCRINOLOGY; FEMALE; HUMANS; HYPERTENSION; MALE; PREVALENCE; PRIMARY HEALTH CARE;

EID: 1642359850     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Ubink-Veltmaat LJ, Bilo HJG, Groenier KH, Houweling ST, Rischen RO, Meyboom-de Jong B. Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in the Netherlands (ZODIAC-1). Eur J Epidemiol 2003;18:793-800.
2. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974;23:105-11.
3. Uusitupa MI, Niskanen NJ, Siitonen O, Voutilainen E, Pyörä lä K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1993;36:1175-84.
4. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, et al. A prospective study of maturity-onset diabetes mellitus and the risk of coronary heart disease and stroke in women. Arch Intern Med 1991;151:1141-7.
5. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the Multiple risk factor intervention trial. Diabetes Care 1993;16:434-43.
6. Feskens EJM, Kromhout D. Diabetes mellitus en hart- en vaatziekten. Resultaten uit het Zutphen onderzoek. Hart Bulletin 1992;23:26-9.
7. Mooy JM. Non-insulin-dependent diabetes mellitus in a general caucasian population [proefschrift]. Amsterdam: Vrije Universiteit; 1995.
8. Sprafka JM, Bender AP, Jagger HG. Prevalence of hypertension and associated risk factors among diabetic individuals. The Three-City-Study. Diabetes Care 1988;11:17-22.
9. Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994;17:1247-51.
10. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, et al. Effects of calcium channel blockers in older patients with diabetes and systolic hypertension. Systolic hypertension in Europe trial. N Engl J Med 1999;340:677-84.
11. UKPDS Group. UK prospective diabetes study 38. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998;317:703-13.
12. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure-lowering and low dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. The HOT Study Group. Lancet 1998;351:1755-62.
13. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW, The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
14. Tatti P, Pahor M, Byington RP, DiMauro P, Guaresco R, Strollo G, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:579-603.
15. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6.
16. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996;276:1886-92.
17. Davis BR, Langford HG, Blaufox, Curb JD, Polk BF, Shulman NB. The association of postural changes in systolic blood pressure and mortality in persons with hypertension: the Hypertension Detection and Follow-up Program experience. Circulation 1987;75:340-46.
18. Lindholm LH, Hansson L, Ekbom T, Dahlöf B, Lanke J, Linjer E, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000;18:1671-5.
19. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-64.
20. Brown MJ, Palmer CR, Castaigne A, Leeuw PW de, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72.
21. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation (HOPE). Lancet 2000;355:253-9.
22. Dahlof B, Devereux RIB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
23. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blockers vs diuretics: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
24. Cromme PVM, Mulder JD, Rutten GEHM, Zuidweg J, Thomas S. NHG-standaard Diabetes mellitus type II. Huisarts Wet 1989;32:509-12.
25. Rutten GEHM, Verhoeven S, Heine RJ, Grauw WJC de, Cromme PVM, Reenders K, et al. NHG-standaard Diabetes mellitus type 2 (eerste herziening). Huisarts Wet 1999;42:67-84.
26. Centraal Begeleidingsorgaan voor de Intercollegiale Toetsing (CBO). Richtlijnen NDF/CBO diabetische retinopathie, diabetische voet, hart- en vaatziekten bij diabetes mellitus. Utrecht: CBO; 1998.
27. Kwaliteitsinstituut voor de Gezondheidszorg CBO (CBO). Herziening richtlijn hoge bloeddruk. Utrecht: CBO; 2000.
28. Renders CM, Valk GD, Franse LV, Schellevis FG, Eijk JT van, Wal G van der. Long-term effectiveness of a quality improvement program for patients with type 2 diabetes in general practice. Diabetes Care 2001;24:1365-70.
29. Does FE van der, Neeling JN de, Kostense PJ, Grootenhuis PA, Bouter LM, Heine RJ. Symptoms and well-being in relation to glycemic control in type II diabetes. Diabetes Care 1996;19:204-10.
30. Rutten GE, Maaijen J, Valkenburg AC, Blankestijn JG, Valk HW de. The Utrecht Diabetes Project: telemedicine support improves GP care in type 2 diabetes. Diabetes Medicine 2001;18:459-63.
31. Sonnaville JJ de, Bouma M, Colly LP, Devillé W, Wijkel D, Heine RJ. Sustained good glycaemic control in NIDDM patients by implementation of structured care in general practice: 2-year follow-up study. Diabetologia 1997;40:1334-40.
32. Bouma M, Dekker JH, Eijk JT van, Schellevis FG, Kriegsman DMW, Heine RJ. Metabolic control and morbidity of type 2 diabetes patients in a general practice network. Family Practice 1999;16:402-6.
33. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertension 1999;17:151-83.
34. Nilsson PM, Gudbjornsdottir S, Eliasson B, Cederholm J. Hypertension in diabetes: trends in clinical control in repeated large-scale national surveys from Sweden. J Hum Hypertens 2003;17:37-44.
35. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl. J Med 2003;348:383-93.
36. Bakris GL, Weir MR. Study of hypertension and the efficacy of lotrel in diabetes (SHIELD) investigators. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens 2003;5:202-9.
37. Katayama S, Inaba M, Morita T, Awata T, Shimamoto K, Kikkawa R. Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus. Hypertens Res 2000;23:601-5.
38. Charpentier G, Genes N, Vaur L, Amar J, Clerson P, Cambou JP, et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey. ESPOIR Diabetes Study Investigators. Diabetes Metab 2003;29:152-8.
39. Grant RW, Cagliero E, Murphy-Sheehy P, Singer DE, Nathan DM, Meigs JB. Comparison of hyperglycemia, hypertension hypercholesterolemia management in patients with type 2 diabetes. Am J Med 2002;112:603-9.
40. Miller CD, Philips LS, Tate MK, Porwoll JM, Rossman SD, Cronmiller N, et al. Meeting American Diabetes Association Guidelines in endocrinologist practice. Diabetes Care 2000;23:444-8.
41. Berlowitz DR, Arlene SA, Hickey EC, Glickman M, Friedman R, Kader B. Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care 2003;26:355-9.
42. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LIP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997;336:1117-24.